Incannex Lands A$6M R&D Tax Refund, Projects A$11M+ Non-Dilutive Funding
IXHL sits 51% above its 52-week low of $2.49.
Summary
Incannex Healthcare received A$6.04 million (approx. US$4.0M) from an R&D tax incentive and expects over A$11.1 million (approx. US$7.3M) in total non-dilutive funding for 2026. This significantly strengthens the company's balance sheet, adding to its $74.5 million cash reported in the May 15th 10-Q. The non-dilutive nature of these funds is key, providing capital to advance clinical programs like IHL-42X and PSX-001 without issuing new shares. This also supports the company's active share repurchase program and extends its financial runway.
At the time of this announcement, IXHL was trading at $3.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.9M. The 52-week trading range was $2.49 to $49.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.